Former Swedish Prime Minister, former president of the European Council Mr. Fredrik Reinfeldt and Executive Chairman of Nordic Growth Technology (NGT) Partners, professor Niclas Adler visited Biocytogen on January 23, 2019. This visit was accompanied by Dr. Zhi Yang, founding Partner of BioVeda China Fund. Biocytogen’s CEO Dr. Yuelei Shen, CSO Dr. Yi Yang, and Director of Pharmacology Department Dr. Yanan Guo welcomed the visitors.
Dr. Shen introduced Biocytogen and emphasized the unique strengths in its four service platforms including gene-edited animal customization, animal disease model development and production, efficacy preclinical services, and antibody development.
Mr. Adler discussed efforts from NGT-Partners and the Royal Caroline Institute in global R&D of innovative medicines. He praised Biocyogen for its products and services and commented that advanced animal disease models are instrumental in pharmaceutical R&D, and key to translational medicine. He added that compared with other CROs, Biocytogen builds on its cutting-edge gene editing technology and expands to offer various disease models and antibody preclinical services.
“It is admiring to see the rapid growth of Biocytogen. As a fully integrated biomedical CRO (contract research organization) company, Biocytogen has huge potentials in antibody drug development, selection, and efficacy studies. We look forward to strengthening collaborations in antibody drug R&D.”
After the meeting, Mr. Reinfeldt and other guests visited Biocytogen’s gene editing laboratories and antibody drug development laboratories. Further discussions included case studies on the preclinical services for biopharma and biotech companies worldwide.